Skip to main content
OpenTrials
Completed

NCT Number: NCT04397809

Utility of CD64 and TLR2 Assays to Diagnose Acute Pulmonary Exacerbations in Cystic Fibrosis

Cystic fibrosis (CF) is the most common inherited disease in the western world. On a yearly basis, 56% of CF patients, or nearly 17,000 individuals in the US, suffer from acute pulmonary exacerbations (APE). The purpose of this study is to test a candidate assay for its ability to diagnose APE, the most important disease event in CF. While previous studies have been able to identify biomarkers of CF prognosis and risk stratification, three markers have demonstrated characteristics ideal for APE diagnosis: CD64, TLR2, and GILT. CD64 is a cellular receptor, expressed on numerous cells of the immune system, whose role is to bind antibodies which are attached to infected cells or pathogens. TLR2 plays a major role in early host-microbial interactions. GILT has been shown to be more precise in targeting immune responses against antigens and influences T lymphocyte response. This study looks to identify the differences in the expression of neutrophil CD64 and CD4+ T cell TLR2 and GILT between acute illness and baseline health as a sensitive marker of acute pulmonary exacerbation so that it may facilitate rapid hematologic diagnosis of the condition. The study also looks to compare sensitivity and specificity of the assays above to standard measures, such as health related quality of life scores (CFQ-R), loss of lung function, white blood cell counts and CRP, for diagnosing acute exacerbations.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Jewish Health

Denver, Colorado, 80206, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Documented diagnosis of CF.
  • Age 18 years old or greater.
  • Presentation at baseline health OR at the start of treatment for a pulmonary exacerbation of CF.
  • Ability to perform reproducible Pulmonary Function Tests
  • Ability to produce sputum.
  • Willingness to complete a health-related quality of life questionnaire
  • Willingness to comply with study procedure and provide written consent.

Exclusion criteria

  • Presence of a condition or abnormality that, in the opinion of the Principal Investigator (PI), would compromise the safety of the patient or the quality of the data.

Treatment and study plan

Primary outcomes

  1. Difference in neutrophil CD64 expression

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    The primary outcome measure is the difference in expression of neutrophil CD64 as measured by flow cytometry from circulating blood between the two groups (APE and baseline).

  2. Difference in CD4+ T cell TLR2 expression

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    The primary outcome measure is the difference in expression of CD4+ T cell TLR2 as measured by flow cytometry from circulating blood between the two groups (APE and baseline).

  3. Difference in GILT expression

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    The primary outcome measure is the difference in expression of GILT as measured by flow cytometry from circulating blood between the two groups (APE and baseline).

Secondary outcomes

  1. Correlation of primary outcome measurements with lung function tests

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    A secondary outcome measure is the correlation of the differences in expression of neutrophil CD64, CD4+ T cell TLR2, and GILT with changes in FEV1 as measured by spirometry.

  2. Correlation of primary outcome measurements with C-Reactive Protein

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    A secondary outcome measure is the correlation of the differences in expression of neutrophil CD64, CD4+ T cell TLR2, and GILT with differences in C-Reactive Protein (CRP)

  3. Correlation of primary outcome measurements with total white blood cell counts

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    A secondary outcome measure is the correlation of the differences in expression of neutrophil CD64, CD4+ T cell TLR2, and GILT with differences in total white blood cell counts (WBC).

  4. Correlation of primary outcome measurements with sputum inflammatory markers

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    A secondary outcome measure is the correlation of the differences in expression of neutrophil CD64, CD4+ T cell TLR2, and GILT with differences in sputum inflammatory markers as measured by sputum neutrophil counts and neutrophil elastase expression.

  5. Correlation of primary outcome measurements with phagocytosis

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    A secondary outcome measure is the correlation of the differences in expression of neutrophil CD64, CD4+ T cell TLR2, and GILT with differences in the percentage of phagocytosis by isolated neutrophils.

  6. Correlation of primary outcome measurements with quality of life questionnaire score

    Time frame: Within 24 hours of initiation of IV antibiotic treatment for CF pulmonary exacerbation or at Baseline health

    A secondary outcome measure is the correlation of the differences in expression of neutrophil CD64, CD4+ T cell TLR2, and GILT with differences in patient reported health related quality of life scores as measured by the Cystic Fibrosis Questionnaire-Revised (CFQ-R).

Sponsors and collaborators

Lead sponsor

National Jewish Health

Other

Registry information

Important dates

Study start
2014
Primary completion
2019
Study completion
2021
First posted
May 21, 2020
Registry last updated
Sep 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.